Topics

Scotland's cost regulator rejects Vertex cystic fibrosis drugs

08:51 EDT 15 Aug 2019 | pharmaphorum

Scotland’s cost-effectiveness body has rejected regular NHS funding for Vertex’s cystic fibrosis drugs Orkambi and Symkevi because of concerns about whether their high costs justify uncertain long-term health benefits. The Scottish Medicines Conso...

Original Article: Scotland's cost regulator rejects Vertex cystic fibrosis drugs

NEXT ARTICLE

More From BioPortfolio on "Scotland's cost regulator rejects Vertex cystic fibrosis drugs"

Quick Search